Osteoclast-Released Wnt-10b Underlies Cinacalcet Related Bone Improvement in Chronic Kidney Disease

Cai Mei Zheng, Yung Ho Hsu, Chia Chao Wu, Chien Lin Lu, Wen Chih Liu, Jing Quan Zheng, Yuh Feng Lin, Hui Wen Chiu, Tian Jong Chang, Jia Fwu Shyu, Kuo Cheng Lu

Research output: Contribution to journalArticle

Abstract

Secondary hyperparathyroidism (SHPT) relates to high turnover bone loss and is responsible for most bone fractures among chronic kidney disease (CKD) patients. Changes in the Wingless/beta-catenin signaling (Wnt/β-catenin) pathway and Wnt inhibitors have been found to play a critical role in CKD related bone loss. A calcimimetic agent, cinacalcet, is widely used for SHPT and found to be similarly effective for parathyroidectomy clinically. A significant decrease in hip fracture rates is noted among US hemodialysis Medicare patients since 2004, which is probably related to the cinacalcet era. In our previous clinical study, it was proven that cinacalcet improved the bone mineral density (BMD) even among severe SHPT patients. In this study, the influence of cinacalcet use on bone mass among CKD mice was determined. Cinacalcet significantly reduced the cortical porosity in femoral bones of treated CKD mice. It also improved the whole-bone structural properties through increased stiffness and maximum load. Cinacalcet increased femoral bone wingless 10b (Wnt10b) expression in CKD mice. In vitro studies revealed that cinacalcet decreased osteoclast bone resorption and increased Wnt 10b release from osteoclasts. Cinacalcet increased bone mineralization when culturing the osteoblasts with cinacalcet treated osteoclast supernatant. In conclusion, cinacalcet increased bone quantity and quality in CKD mice, probably through increased bone mineralization related with osteoclast Wnt 10b secretion.

Original languageEnglish
JournalInternational Journal of Molecular Sciences
Volume20
Issue number11
DOIs
Publication statusPublished - Jun 8 2019

Fingerprint

kidney diseases
Osteoclasts
Chronic Renal Insufficiency
bones
Bone
Bone and Bones
Secondary Hyperparathyroidism
mice
Physiologic Calcification
Thigh
Calcimimetic Agents
Cinacalcet Hydrochloride
Parathyroidectomy
Wnt Signaling Pathway
Bone Remodeling
Porosity
Bone Fractures
Hip Fractures
osteoblasts
Bone Resorption

Keywords

  • chronic kidney disease
  • cinacalcet
  • osteoclast
  • renal osteodystrophy
  • Wnt 10b

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

Osteoclast-Released Wnt-10b Underlies Cinacalcet Related Bone Improvement in Chronic Kidney Disease. / Zheng, Cai Mei; Hsu, Yung Ho; Wu, Chia Chao; Lu, Chien Lin; Liu, Wen Chih; Zheng, Jing Quan; Lin, Yuh Feng; Chiu, Hui Wen; Chang, Tian Jong; Shyu, Jia Fwu; Lu, Kuo Cheng.

In: International Journal of Molecular Sciences, Vol. 20, No. 11, 08.06.2019.

Research output: Contribution to journalArticle

@article{4ff46bc3e47643c3af32b6e9f3d515bd,
title = "Osteoclast-Released Wnt-10b Underlies Cinacalcet Related Bone Improvement in Chronic Kidney Disease",
abstract = "Secondary hyperparathyroidism (SHPT) relates to high turnover bone loss and is responsible for most bone fractures among chronic kidney disease (CKD) patients. Changes in the Wingless/beta-catenin signaling (Wnt/β-catenin) pathway and Wnt inhibitors have been found to play a critical role in CKD related bone loss. A calcimimetic agent, cinacalcet, is widely used for SHPT and found to be similarly effective for parathyroidectomy clinically. A significant decrease in hip fracture rates is noted among US hemodialysis Medicare patients since 2004, which is probably related to the cinacalcet era. In our previous clinical study, it was proven that cinacalcet improved the bone mineral density (BMD) even among severe SHPT patients. In this study, the influence of cinacalcet use on bone mass among CKD mice was determined. Cinacalcet significantly reduced the cortical porosity in femoral bones of treated CKD mice. It also improved the whole-bone structural properties through increased stiffness and maximum load. Cinacalcet increased femoral bone wingless 10b (Wnt10b) expression in CKD mice. In vitro studies revealed that cinacalcet decreased osteoclast bone resorption and increased Wnt 10b release from osteoclasts. Cinacalcet increased bone mineralization when culturing the osteoblasts with cinacalcet treated osteoclast supernatant. In conclusion, cinacalcet increased bone quantity and quality in CKD mice, probably through increased bone mineralization related with osteoclast Wnt 10b secretion.",
keywords = "chronic kidney disease, cinacalcet, osteoclast, renal osteodystrophy, Wnt 10b",
author = "Zheng, {Cai Mei} and Hsu, {Yung Ho} and Wu, {Chia Chao} and Lu, {Chien Lin} and Liu, {Wen Chih} and Zheng, {Jing Quan} and Lin, {Yuh Feng} and Chiu, {Hui Wen} and Chang, {Tian Jong} and Shyu, {Jia Fwu} and Lu, {Kuo Cheng}",
year = "2019",
month = "6",
day = "8",
doi = "10.3390/ijms20112800",
language = "English",
volume = "20",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "MDPI AG",
number = "11",

}

TY - JOUR

T1 - Osteoclast-Released Wnt-10b Underlies Cinacalcet Related Bone Improvement in Chronic Kidney Disease

AU - Zheng, Cai Mei

AU - Hsu, Yung Ho

AU - Wu, Chia Chao

AU - Lu, Chien Lin

AU - Liu, Wen Chih

AU - Zheng, Jing Quan

AU - Lin, Yuh Feng

AU - Chiu, Hui Wen

AU - Chang, Tian Jong

AU - Shyu, Jia Fwu

AU - Lu, Kuo Cheng

PY - 2019/6/8

Y1 - 2019/6/8

N2 - Secondary hyperparathyroidism (SHPT) relates to high turnover bone loss and is responsible for most bone fractures among chronic kidney disease (CKD) patients. Changes in the Wingless/beta-catenin signaling (Wnt/β-catenin) pathway and Wnt inhibitors have been found to play a critical role in CKD related bone loss. A calcimimetic agent, cinacalcet, is widely used for SHPT and found to be similarly effective for parathyroidectomy clinically. A significant decrease in hip fracture rates is noted among US hemodialysis Medicare patients since 2004, which is probably related to the cinacalcet era. In our previous clinical study, it was proven that cinacalcet improved the bone mineral density (BMD) even among severe SHPT patients. In this study, the influence of cinacalcet use on bone mass among CKD mice was determined. Cinacalcet significantly reduced the cortical porosity in femoral bones of treated CKD mice. It also improved the whole-bone structural properties through increased stiffness and maximum load. Cinacalcet increased femoral bone wingless 10b (Wnt10b) expression in CKD mice. In vitro studies revealed that cinacalcet decreased osteoclast bone resorption and increased Wnt 10b release from osteoclasts. Cinacalcet increased bone mineralization when culturing the osteoblasts with cinacalcet treated osteoclast supernatant. In conclusion, cinacalcet increased bone quantity and quality in CKD mice, probably through increased bone mineralization related with osteoclast Wnt 10b secretion.

AB - Secondary hyperparathyroidism (SHPT) relates to high turnover bone loss and is responsible for most bone fractures among chronic kidney disease (CKD) patients. Changes in the Wingless/beta-catenin signaling (Wnt/β-catenin) pathway and Wnt inhibitors have been found to play a critical role in CKD related bone loss. A calcimimetic agent, cinacalcet, is widely used for SHPT and found to be similarly effective for parathyroidectomy clinically. A significant decrease in hip fracture rates is noted among US hemodialysis Medicare patients since 2004, which is probably related to the cinacalcet era. In our previous clinical study, it was proven that cinacalcet improved the bone mineral density (BMD) even among severe SHPT patients. In this study, the influence of cinacalcet use on bone mass among CKD mice was determined. Cinacalcet significantly reduced the cortical porosity in femoral bones of treated CKD mice. It also improved the whole-bone structural properties through increased stiffness and maximum load. Cinacalcet increased femoral bone wingless 10b (Wnt10b) expression in CKD mice. In vitro studies revealed that cinacalcet decreased osteoclast bone resorption and increased Wnt 10b release from osteoclasts. Cinacalcet increased bone mineralization when culturing the osteoblasts with cinacalcet treated osteoclast supernatant. In conclusion, cinacalcet increased bone quantity and quality in CKD mice, probably through increased bone mineralization related with osteoclast Wnt 10b secretion.

KW - chronic kidney disease

KW - cinacalcet

KW - osteoclast

KW - renal osteodystrophy

KW - Wnt 10b

UR - http://www.scopus.com/inward/record.url?scp=85067828956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067828956&partnerID=8YFLogxK

U2 - 10.3390/ijms20112800

DO - 10.3390/ijms20112800

M3 - Article

VL - 20

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 11

ER -